Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 9:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 1,351 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Digestive System Abnormalities Clear all
Completed Not applicable Interventional

Randomized Study of Alendronate in Adult Patients With Cystic Fibrosis Related Osteoporosis

NCT00004489
View directory record Official record
Conditions
Osteoporosis, Cystic Fibrosis
Interventions
alendronate sodium, calcium carbonate, cholecalciferol
Drug
Lead sponsor
University of North Carolina
Other
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 29, 2026, 9:54 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI)

NCT00408317
View directory record Official record
Conditions
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions
Ultrase® MT20, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
7 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Grand Rapids, Michigan • Cleveland, Ohio • Hershey, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 29, 2026, 9:54 PM EDT
Completed No phase listed Observational

Comparing Chest Images From MRI to CT in Patients With Cystic Fibrosis (CF)

NCT01860872
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 60 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 24, 2020 · Synced Oct 29, 2026, 9:54 PM EDT
Recruiting No phase listed Observational

Clinical and Basic Investigations Into Hermansky-Pudlak Syndrome

NCT00001456
View directory record Official record
Conditions
Hermansky-Pudlak Syndrome (HPS)
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
1 Month to 115 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 29, 2026, 9:54 PM EDT
Completed Phase 1 Interventional

High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer

NCT00002854
View directory record Official record
Conditions
Cancer
Interventions
filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, ifosfamide, mesna, paclitaxel, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2015
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Oct 29, 2026, 9:54 PM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

NCT03207867
View directory record Official record
Conditions
NSCLC, Non Small Cell Lung Cancer, RCC, Renal Cell Cancer, Pancreatic Cancer, Urothelial Cancer, Head and Neck Cancer, DLBCL, Diffused Large B Cell Lymphoma, MSS, Microsatellite Stable Colon Cancer, TNBC, Triple Negative Breast Cancer, Melanoma, mCRPC, Metastatic Castration Resistant Prostate Cancer
Interventions
NIR178, PDR001
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
5
States / cities
Santa Monica, California • Tampa, Florida • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 29, 2026, 9:54 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors

NCT04377932
View directory record Official record
Conditions
Liver Cancer, Rhabdomyosarcoma, Malignant Rhabdoid Tumor, Liposarcoma, Wilms Tumor, Yolk Sac Tumor
Interventions
AGAR T cells
Genetic
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 21 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2040
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 29, 2026, 9:54 PM EDT
Recruiting No phase listed Observational

A Personalized Surveillance and Intervention Protocol for Duodenal and Gastric Polyposis in Patients With Familial Adenomatous Polyposis

NCT04677998
View directory record Official record
Conditions
Familial Adenomatous Polyposis
Interventions
Personalized surveillance and intervention protocol
Procedure
Lead sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 29, 2026, 9:54 PM EDT
Completed Phase 1 Interventional

A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP)

NCT02452372
View directory record Official record
Conditions
Acute Intermittent Porphyria
Interventions
givosiran (ALN-AS1), Sterile Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Birmingham, Alabama • San Francisco, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 29, 2026, 9:54 PM EDT
Completed Phase 3 Interventional Results available

Rollover Study of VX-770 in Cystic Fibrosis Subjects

NCT01117012
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
36
States / cities
Birmingham, Alabama • Oakland, California • Palo Alto, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2015 · Synced Oct 29, 2026, 9:54 PM EDT
Completed Not applicable Interventional Results available

Impact of Discontinuing Dornase Alfa in People With CF on Highly Effective CFTR Modulator Therapy-A SIMPLIFY Sub-Study

NCT06350474
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Discontinuation of dornase alfa (Dnase), Continuation of dornase alfa (Dnase)
Other
Lead sponsor
Nicole Hamblett
Other
Eligibility
12 Years and older
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
81
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 29, 2026, 9:54 PM EDT
Terminated No phase listed Observational

A Multi-Center Study of the CF Quantum® Sweat Test System

NCT02404714
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Iontophoresis sweat test
Device
Lead sponsor
Polychrome Medical, Inc.
Industry
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Birmingham, Alabama • Chicago, Illinois • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 29, 2026, 9:54 PM EDT
Completed Phase 2 Interventional Results available

Effect of Double Dose of Alpha 1-antitrypsin Augmentation Therapy on Lung Inflammation.

NCT01669421
View directory record Official record
Conditions
Alpha 1 Antitrypsin Deficiency
Interventions
Alpha-1 Antitrypsin (human)
Drug
Lead sponsor
Michael Campos, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Oct 29, 2026, 9:54 PM EDT
Recruiting Phase 4 Interventional

Estrogen Supplementation and Bone Health in Women With CF

NCT05704036
View directory record Official record
Conditions
Cystic Fibrosis, Hypoestrogenism
Interventions
Transdermal estrogen, Progesterone
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
0 Years to 100 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 29, 2026, 9:54 PM EDT
Terminated No phase listed Observational

A Study to Identify and Characterize LAL-D Patients in High-risk Populations

NCT02345421
View directory record Official record
Conditions
Lysosomal Acid Lipase Deficiency
Interventions
Not listed
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
2 Years and older
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 24, 2016 · Synced Oct 29, 2026, 9:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Effect of L. Reuteri on Biomarkers of Inflammation in Healthy Infants With Colic

NCT01849991
View directory record Official record
Conditions
Gastrointestinal, Colic
Interventions
Lactobacillus reuteri, Placebo
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
3 Weeks to 3 Months
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Oct 29, 2026, 9:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Relative Bioavailability of a Fixed-dose Combination Tablet of VX-121/Tezacaftor/Deutivacaftor

NCT05535959
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-121/TEZ/D-IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Oct 29, 2026, 9:54 PM EDT
Recruiting No phase listed Observational

Sinus Disease in Young Children With Cystic Fibrosis

NCT06191640
View directory record Official record
Conditions
Cystic Fibrosis in Children, Cystic Fibrosis, Chronic Rhinosinusitis (Diagnosis), Olfactory Disorder, Olfactory Impairment
Interventions
Ivacaftor or elexacaftor/tezacaftor/ivacaftor
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
2 Years to 8 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
6
States / cities
Aurora, Colorado • Iowa City, Iowa • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 29, 2026, 9:54 PM EDT
Recruiting Phase 1 Interventional

Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors

NCT04715191
View directory record Official record
Conditions
Liver Cancer, Rhabdomyosarcoma, Malignant Rhabdoid Tumor, Liposarcoma, Wilms Tumor, Yolk Sac Tumor
Interventions
CARE T cells
Genetic
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2042
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 29, 2026, 9:54 PM EDT
Recruiting Phase 1Phase 2 Interventional

FOG-001 in Locally Advanced or Metastatic Solid Tumors

NCT05919264
View directory record Official record
Conditions
Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor, Metastatic Cancer, WNT Pathway, HCC, Desmoid, Microsatellite Stable Colorectal Cancer, Metastatic Castration-resistant Prostate Cancer, Familial Adenomatous Polyposis (FAP), Endometrial Carcinoma, Prostate Cancer, Microsatellite Instability-High Colorectal Cancer, Adamantinomatous Craniopharyngioma
Interventions
FOG-001, mFOLFOX-6, Nivolumab, Trifluridine/tipiracil, Bevacizumab
Drug
Lead sponsor
Parabilis Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
619 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 29, 2026, 9:54 PM EDT
Completed Not applicable Interventional

Pilot Study to Evaluate a Voice Journaling Application in Adolescents With Cystic Fibrosis

NCT05420844
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Kintsugi voice journaling application
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
14 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 29, 2026, 9:54 PM EDT
Terminated Phase 1 Interventional

Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

NCT03114319
View directory record Official record
Conditions
Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal Squamous Cell Cancer (SCC), Head/Neck SCC, Melanoma, Advanced Gastrointestinal Stromal Tumors (GIST), Advanced NRAS/BRAFT wt Cutaneous Melanoma
Interventions
TNO155, TNO155 in combination with EGF816 (nazartinib)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
4
States / cities
Tampa, Florida • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 29, 2026, 9:54 PM EDT
Completed Phase 2 Interventional

Study of LYM-X-SORB™ to Improve Fatty Acid and Choline Status in Children With CF and PI

NCT00406536
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency
Interventions
Lym-X-Sorb powder, Placebo powder
Dietary Supplement
Lead sponsor
Avanti Polar Lipids, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 14, 2013 · Synced Oct 29, 2026, 9:54 PM EDT
Completed Phase 1 Interventional

A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

NCT04670679
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors
Interventions
ERAS-601, Cetuximab, Pembrolizumab
Drug
Lead sponsor
Erasca, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
12
States / cities
Birmingham, Alabama • Sarasota, Florida • Boston, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 29, 2026, 9:54 PM EDT